University of Iowa Hospitals | Infectious Diseases Department

Research site

(Unclaimed)

Location

200 Hawkins Dr, Iowa City, Iowa, United States of America

Site insights

Top conditions

Top treatments

Armodafinil

Pembrolizumab

AS1413

ASP1002

ASP2074

Daclizumab

Rucaparib

Gemcitabine

Cytarabine

APL-2

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 25 total trials

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting

FIGO Stage III-IV

Newly Diagnosed

Drug: Placebo Oral Tablet

Drug: Rucaparib

A Study of ASP1002 in Adults for Treatment of Solid Tumors

ASP1002 is a potential new treatment for people with certain solid tumors. Before ASP1002 is available as a treatment, the researchers need to unders...

Enrolling

Advanced Solid Tumors

Drug: ASP1002

A Study of ASP1012 in Adults With Solid Tumors

ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers.ASP1012 was changed in a laboratory to infect and kill cance...

Enrolling

Solid Tumor

Drug: ASP1012

Drug: Pembrolizumab

A Study of ASP2074 in Adults With Solid Tumors

ASP2074 is a potential new treatment for people with certain solid tumors. Before ASP2074 is available as a treatment, the researchers need to unders...

Active, not recruiting

Advanced Solid Tumors

Drug: ASP2074

COVID Protection After Transplant-Immunosuppression Reduction (CPAT-ISR)

This study will enroll individuals who have:* Completed primary series of mRNA COVID-19 vaccine, and* An antibody response ≤ 2500 U/mL measured at le...

Active, not recruiting

Liver Transplant Recipients

Kidney Transplant Recipients

Drug: SOC IS Reduction

Biological: Moderna COVID-19 Vaccine 2023-2024

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

The purpose of the trial is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients wit...

Active, not recruiting

Endometrial Carcinoma

Squamous Cell Carcinoma of the Head and Neck

Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)

Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected...

Enrolling

Advanced Unresectable Solid Tumor

Metastatic Solid Tumor

Drug: Toripalimab

Drug: TAB004